Method, system and equipment for evaluating treatment effect of CCDC71L inhibitor on radiation enteritis

Abstract

The invention discloses a method, a system and equipment for evaluating the treatment effect of a CCDC71L inhibitor on radiation enteritis. It is found for the first time that knock-down of CCDC71L in human colorectal epithelial cells subjected to irradiation treatment can play a role in treating radioactive injury by regulating and controlling a lipid metabolism pathway and a ferroptosis pathway. On the basis, the invention provides a method, a system and equipment for evaluating the treatment effect of the CCDC71L inhibitor on the radiation enteritis for the field, so that a doctor is assisted in evaluating the treatment effect of a patient suffering from the radiation enteritis, and a clinician is guided to formulate an individualized treatment scheme for the patient.

Description

Technical Field

[0001] The present invention belongs to the field of bioinformatics, and specifically, the present invention relates to a method, system and device for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis. Background Art

[0002] Radiotherapy is one of the important means of comprehensive treatment of modern malignant tumors. According to epidemiological statistics, about half of malignant tumor patients need to receive radiotherapy. In recent years, with the improvement of radiotherapy technology, the accuracy of tumor tissue irradiation during radiotherapy has been greatly improved, but radiation damage to normal tissues is still the main reason for dose limitation. Patients with abdominal and pelvic tumors often suffer from radiation enteritis when receiving radiotherapy, with clinical manifestations of abdominal distension, abdominal pain, diarrhea and bloody stools. In severe cases, intestinal perforation or intestinal obstruction may occur. Therefore, the development of safe and effective therapeutic drugs or methods and the evaluation of the therapeutic effects of drugs are crucial to improving the quality of life of patients.

[0003] Previous studies have shown that CCDC71L is closely related to the occurrence of many diseases, but its mechanism of action is unknown. The results of genomic analysis of atherosclerosis showed that CCDC71L, as an upstream gene of PIK3CG, is associated with atherosclerosis. In cancer, CCDC71L has been shown to be a major regulator in triple-negative breast cancer, which is associated with regulating the proliferation, migration and invasion of tumor cells. However, the relationship between CCDC71L and radiation enteritis and its mechanism of regulating radiation enteritis are still unclear. Summary of the invention

[0004] In order to make up for the deficiencies of the prior art, the purpose of the present invention is to study the mechanism of action of CCDC71L in regulating radiation enteritis, and further provide a method, system and equipment for evaluating the therapeutic effect of CCDC71L inhibitors on radiation enteritis.

[0005] In order to achieve the above object, the present invention adopts the following technical solution: The first aspect of the present invention provides a method for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis.

[0006] Furthermore, the method is performed by a computer and comprises the following steps: Acquiring data: Acquiring the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins in samples of patients with radiation enteritis after treatment with CCDC71L inhibitors; Processing data: inputting the expression data obtained above into a constructed evaluation model, wherein the evaluation model predicts the therapeutic effect of CCDC71L inhibitor on patients with radiation enteritis based on the expression data of the ferroptosis-related protein and / or the lipid metabolism-related protein; Output the result.

[0007] Further, the steps of constructing the evaluation model are as follows: Obtain expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins; the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins are from untreated patients with radiation enteritis and patients with radiation enteritis after treatment with CCDC71L inhibitors; input the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins into a machine learning algorithm to construct an evaluation model.

[0008] Preferably, the step of constructing the evaluation model also includes verifying the model effectiveness, and the method of verifying the model effectiveness includes a ROC curve.

[0009] Furthermore, the ferroptosis-related proteins include one or more of the following: ACSL4, GPX4, and FTH1.

[0010] The lipid metabolism related proteins include one or more of the following: FADS2, SCD1.

[0011] Furthermore, the machine learning algorithm includes algorithm models developed using various development tools.

[0012] Furthermore, the development tools include but are not limited to TensorFlow, Scikit Learn, PyTorch, OpenNN, RapidMiner, Azure Machine Learning, Apache Mahout, Shogun, KNIME, Vertex AI, H2Oai, Anaconda, Keras, Tableau, Fast.ai, Catalyst, Amazon ML, MLJAR, and Spell.

[0013] Furthermore, the algorithm model includes but is not limited to linear regression model, logistic regression model, Lasso regression model, Ridge regression model, linear discriminant analysis model, nearest neighbor model, decision tree model, perceptron model, neural network model, support vector machine model, naive Bayes model, AdaBoost model, GBDT model, XGBoost model, LightGBM model, CatBoost model, and random forest model.

[0014] Furthermore, the evaluation model obtains results through the following criteria: When the expression level of any one or more of ACSL4, FADS2, and SCD1 is lower than a threshold value or the expression level of any one or more of GPX4 and FTH1 is higher than a threshold value, a classification result is obtained that the CCDC71L inhibitor is effective in treating radiation enteritis patients; When the expression levels of any one or more of ACSL4, FADS2, and SCD1 are higher than a threshold or the expression levels of any one or more of GPX4 and FTH1 are lower than a threshold, a classification result is obtained that CCDC71L inhibitor is ineffective in treating radiation enteritis patients.

[0015] In some embodiments of the present invention, the preset threshold is a representative value of normal samples of radiation enteritis patients, including but not limited to a maximum value, a third quartile, and an average value. In some preferred embodiments of the present invention, the population sample includes more than 20 samples, such as 30, 50, 80, 100, 150, 200, 300, 500 or more.

[0016] Furthermore, the patient includes humans and / or mammals.

[0017] Furthermore, the sample includes blood and / or tissue.

[0018] The second aspect of the present invention provides a system for evaluating the therapeutic effect of CCDC71L inhibitors on radiation enteritis.

[0019] Further, the system comprises: Data acquisition unit: used to obtain the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins in samples of patients with radiation enteritis after treatment with CCDC71L inhibitors; A data classification unit is used to classify and predict the data obtained by the data acquisition unit through the evaluation model obtained by the construction method described in the first aspect of the present invention, and obtain a classification result of whether the CCDC71L inhibitor is effective in treating radiation enteritis patients; Result output unit: used to output classification results.

[0020] Furthermore, the ferroptosis-related proteins include one or more of the following: ACSL4, GPX4, and FTH1.

[0021] The lipid metabolism related proteins include one or more of the following: FADS2, SCD1.

[0022] A third aspect of the present invention provides a computer device.

[0023] Further, the device comprises: A memory and a processor, wherein the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, the method for evaluating the therapeutic effect of CCDC71L inhibitor on radiation enteritis described in the first aspect of the present invention is implemented.

[0024] A fourth aspect of the present invention provides a computer-readable storage medium.

[0025] Furthermore, the computer-readable storage medium stores a computer program, and when the computer program is executed by the processor, the method for evaluating the therapeutic effect of CCDC71L inhibitor on radiation enteritis described in the first aspect of the present invention is implemented.

[0026] The fifth aspect of the present invention provides the use of a CCDC71L inhibitor or a pharmaceutical composition containing a CCDC71L inhibitor in the preparation of the following products: 1) Products that inhibit ferroptosis; 2) Products that relieve lipid metabolism disorders; 3) Products that inhibit the expression of ACSL4, FADS2, and / or SCD1; 4) Products that promote GPX4 or FTH1 expression.

[0027] Advantages and beneficial effects of the present invention: The present invention first discovered that knocking down CCDC71L in irradiated human colorectal epithelial cells can play a role in treating radiation damage by regulating lipid metabolism pathways and ferroptosis pathways. Based on this, the present invention provides a method, system and device for evaluating the therapeutic effect of CCDC71L inhibitors on radiation enteritis in the art, thereby assisting doctors in evaluating the therapeutic effect of radiation enteritis patients and guiding clinicians to formulate individualized treatment plans for patients. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 A schematic flow chart of a method for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis provided by the present invention; Figure 2 A schematic diagram of the system structure for evaluating the therapeutic effect of CCDC71L inhibitors on radiation enteritis provided by the present invention; Figure 3 A schematic diagram of the structure of a computer device provided by the present invention; Figure 4It shows that CCDC71L is involved in ionizing radiation-induced intestinal damage by regulating lipid metabolism and ferroptosis pathways; Figure A shows RT-qPCR detection of changes in mRNA expression of CCDC71L, ACSL4, GPX4, FTH1, FADS2 and SCD1 in irradiated human colorectal epithelial cells; Figure B shows Western Blot analysis of changes in protein expression of CCDC71L, ACSL4, GPX4, FTH1, FADS2 and SCD1 in irradiated human colorectal epithelial cells; Figure C shows RT-qPCR detection of changes in mRNA expression of CCDC71L, ACSL4, GPX4, FTH1, FADS2 and SCD1 in irradiated human colorectal epithelial cells with CCDC71L knockdown; Figure D shows Western Blot analysis of changes in protein expression of CCDC71L, ACSL4, GPX4, FTH1, FADS2 and SCD1 in irradiated human colorectal epithelial cells with CCDC71L knockdown. DETAILED DESCRIPTION

[0029] In order to enable those skilled in the art to better understand the solutions of the present invention, the technical solutions in the embodiments of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the embodiments of the present invention.

[0030] In some of the processes described in the specification and claims of the present invention and the above-mentioned figures, multiple operations that appear in a specific order are included, but it should be clearly understood that these operations may not be executed in the order in which they appear in this article or executed in parallel. The serial numbers of the operations, such as 101, 102, etc., are only used to distinguish different operations, and the serial numbers themselves do not represent any execution order. In addition, these processes may include more or fewer operations, and these operations may be executed in sequence or in parallel. It should be noted that the descriptions of "first", "second", etc. in this article are used to distinguish different messages, devices, modules, etc., do not represent the order of precedence, and do not limit the "first" and "second" to be different types.

[0031] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.

[0032] Figure 1 A schematic flow chart of a method for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis provided by the present invention. Specifically, the method comprises: 101: Obtain data, obtain the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins in samples of patients with radiation enteritis after treatment with CCDC71L inhibitors; In some embodiments of the present invention, the applicant has found through extensive and in-depth research that the ferroptosis pathway is activated in irradiated human colorectal epithelial cells and lipid metabolism is disordered. When CCDC71L is knocked out in irradiated human colorectal epithelial cells, it is found that the expression levels of ferroptosis-related proteins and / or lipid metabolism-related proteins change, which suggests that CCDC71L plays an anti-radiation enteritis role by regulating the expression of ferroptosis-related proteins and / or lipid metabolism-related proteins.

[0033] In some embodiments of the present invention, the ferroptosis-related protein includes ACSL4, GPX4 or FTH1. The lipid metabolism-related protein includes FADS2 or SCD1.

[0034] In some embodiments, expression level data of ACSL4, GPX4, FTH1, FADS2 or SCD1 can be obtained by measuring the amount of RNA, mRNA or any other RNA species using methods well known in the art to obtain expression at the nucleic acid level, including digital PCR and real-time (RT) quantitative or semi-quantitative PCR, fluorescence activated cell sorting (FACS) and in situ hybridization.

[0035] In other embodiments, the expression level data of ACSL4, GPX4, FTH1, FADS2 or SCD1 can be obtained by measuring the expression level at the ACSL4, GPX4, FTH1, FADS2 or SCD1 protein level, including mass spectrometry-based quantitative proteomics technology, immunoassay, Western blotting, spectrophotometry, enzyme assay, ultraviolet assay, kinetic assay, electrochemical assay, colorimetric assay, turbidimetric assay, atomic absorption assay, flow cytometry, mass spectrometry flow cytometry or any combination thereof.

[0036] In some embodiments, the patient can be human or non-human, and can include, for example, animal strains or species used as a "model system" for research purposes. Likewise, patients can include adults or adolescents (e.g., children). In addition, patients can refer to any living organism that benefits from the Meconopsis described herein, preferably mammals (e.g., humans or non-humans). Examples of mammals include, but are not limited to, any member of the class of mammals: humans, non-human primates (e.g., chimpanzees), and other apes and monkeys; livestock, such as cattle, horses, sheep, goats, pigs; domestic animals, such as rabbits, dogs, and cats; experimental animals include rodents, such as rats, mice, and guinea pigs, etc. Examples of non-mammals include, but are not limited to, birds, fish, etc.

[0037] In the context of the present invention, the term "sample" as used herein refers to a composition obtained from or derived from a patient / subject, which contains cells and / or other molecular entities to be characterized and / or identified based on, for example, physical, biochemical, chemical and / or physiological characteristics. For example, a sample refers to any sample derived from a patient / subject that is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue samples, primary or cultured cells or cell lines, cell cultures, cell supernatants, cell lysates, platelets, serum, plasma, vitreous humor, lymphatic fluid, synovial fluid, follicular fluid, semen, pancreatic juice, amniotic fluid, milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tissue culture fluid, tissue extracts, homogenized tissues, cell extracts, and combinations thereof.

[0038] In the present invention, an inhibitor refers to an inhibitor that can specifically bind to CCDC71L, preferably human CCDC71L, or bind to a polynucleotide or a fragment of CCDC71L, and inhibit the activity and / or expression of CCDC71L protein or polynucleotide, including nucleic acid inhibitors, protein inhibitors, and compounds.

[0039] In an embodiment of the present invention, the inhibitor is selected from nucleic acid inhibitors, including siRNA, shRNA, ribozyme, antisense oligonucleotide. In a specific embodiment of the present invention, the nucleic acid inhibitor is shRNA.

[0040] Studies have reported that the ferroptosis process and lipid metabolism process of intestinal epithelial cells are closely related to the progression of radiation enteritis. In one embodiment of the present invention, in order to preliminarily explore the mechanism of action of CCDC71L in intestinal damage induced by ionizing radiation, the applicant detected the expression changes of CCDC71L and ferroptosis- and lipid metabolism-related proteins in irradiated human colorectal epithelial cells. The results showed that irradiation induced upregulation of CCDC71L expression, while the expression of ferroptosis marker ACSL4 increased, and the expression of GPX4 and FTH1 decreased, indicating that radiation enteritis is accompanied by the activation of ferroptosis pathways; in addition, the expression of key lipid metabolism enzymes FADS2 and SCD1 was also significantly upregulated, indicating that radiation enteritis is also accompanied by lipid metabolism disorders ( Figure 4 AB). To further verify whether CCDC71L is associated with ferroptosis and lipid metabolism, we knocked down CCDC71L in irradiated human colorectal epithelial cells and found that CCDC71L knockdown could significantly inhibit the upregulation of FADS2, SCD1, and ACSL4, and alleviate the decrease of GPX4 ( Figure 4CD). These results suggest that CCDC71L promotes lipid metabolism disorders by positively regulating FADS2 and SCD1, and induces ferroptosis through the ACSL4-GPX4 axis, thereby participating in the intestinal injury process induced by ionizing radiation. This shows that CCDC71L inhibitors exert their effects by inhibiting ferroptosis and lipid disorders, suggesting that we can use ferroptosis- and lipid metabolism-related proteins as markers to evaluate the effects of CCDC71L inhibitors.

[0041] 102: Processing data, inputting the expression data obtained in the above 101 into a constructed evaluation model, wherein the evaluation model predicts the therapeutic effect of CCDC71L inhibitor on radiation enteritis patients based on the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins; Furthermore, the ferroptosis-related protein includes ACSL4, GPX4 or FTH1. The lipid metabolism-related protein includes FADS2 or SCD1.

[0042] In some embodiments of the present invention, the method of constructing the evaluation model is known to those skilled in the art, and the step of associating the expression level of ACSL4, GPX4, FTH1, FADS2 and / or SCD1 with a certain possibility or risk can be implemented and realized in different ways.

[0043] In the context of the present invention, the term "machine learning" refers to the use of computers to simulate or implement human learning activities, and technicians usually use different development tools to build machine learning algorithm models. The development tools include but are not limited to TensorFlow, Scikit Learn, PyTorch, OpenNN, RapidMiner, Azure Machine Learning, ApacheMahout, Shogun, KNIME, Vertex AI, H2Oai, Anaconda, Keras, Tableau, Fast.ai, Catalyst, Amazon ML, MLJAR, Spell. The algorithm model includes but is not limited to a linear regression model, a logistic regression model, a Lasso regression model, a Ridge regression model, a linear discriminant analysis model, a neighbor model, a decision tree model, a perceptron model, a neural network model, a support vector machine model, a naive Bayes model, an AdaBoost model, a GBDT model, an XGBoost model, a LightGBM model, a CatBoost model, or a random forest model.

[0044] In one embodiment, after the evaluation model is constructed, the performance of the model can be evaluated using ROC curve analysis.

[0045] ROC curve is a graph of the true positive rate (sensitivity) of a test against the false positive rate (100%-specificity) of the test. It is useful for describing the performance of a specific feature when distinguishing between two populations. Typically, feature data is selected across the entire population in ascending order based on the value of a single feature. Then, for each value of the feature, the true positive and false positive rates of the data are calculated. The true positive rate is determined by counting the number of cases with a value higher than the feature and divided by the total number of cases. The false positive rate is determined by counting the number of controls with a value higher than the feature and divided by the total number of controls. Although this definition refers to the case where the feature is increased compared to the control, the definition is also applied to the case where the feature is lower compared to the control (in this case, the sample with a value lower than the feature will be counted). ROC curves can be generated with respect to individual features, and can be generated with respect to other individual outputs, for example, a combination of two or more features can be combined with mathematical methods (e.g., addition, subtraction, multiplication, etc.) to provide a separate sum value, and the separate sum value can be plotted in the ROC curve. Additionally, any combination of multiple features where the combination is derived from separate output values ​​can be plotted in a ROC curve.

[0046] 103: Output results.

[0047] Figure 2 A schematic diagram of the system structure for evaluating the therapeutic effect of CCDC71L inhibitors on radiation enteritis provided by the present invention; The system is programmed or otherwise configured to include a data acquisition unit 201, a data classification unit 202, and a result output unit 203: Data acquisition unit 201: used to obtain expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins in samples of radiation enteritis patients after treatment with CCDC71L inhibitors; Data classification unit 202: used to classify and predict the data obtained by the data acquisition unit through the evaluation model obtained by the construction method described in the first aspect of the present invention, and obtain a classification result of whether the CCDC71L inhibitor is effective in treating radiation enteritis patients; Result output unit 203: used to output classification results.

[0048] The system may be the user's electronic device or a computer system located remotely from the electronic device.

[0049] The ferroptosis-related proteins include ACSL4, GPX4 or FTH1. The lipid metabolism-related proteins include FADS2 or SCD1.

[0050] Figure 3 A schematic diagram of the structure of a computer device provided by the present invention.

[0051] The computer device 300 includes a processor 301 and a memory 302 coupled to the processor 301 . The memory 302 stores program instructions. When the program instructions are executed by the processor 301 , the processor 301 executes the above-mentioned method for evaluating the therapeutic effect of CCDC71L inhibitor on radiation enteritis.

[0052] The processor 301 may also be referred to as a CPU (Central Processing Unit). The processor 301 may be an integrated circuit chip having signal processing capabilities. The processor 301 may also be a general-purpose processor, a digital signal processor (DSP), an application-specific integrated circuit (ASIC), a field programmable gate array (FPGA) or other programmable logic devices, discrete gate or transistor logic devices, discrete hardware components. The general-purpose processor may be a microprocessor or the processor may also be any conventional processor, etc.

[0053] The computer device 300 may be a mobile electronic device.

[0054] It should be understood that the systems, devices and methods described in the present invention can be implemented in other ways. For example, the device embodiments described above are only schematic. For example, the division of the modules is only a logical function division. There may be other division methods in actual implementation, such as multiple modules or components can be combined or integrated into another system, or some features can be ignored or not executed. Another point is that the mutual coupling or direct coupling or communication connection shown or discussed can be an indirect coupling or communication connection through some interfaces, devices or modules, which can be electrical, mechanical or other forms.

[0055] The modules described as separate components may or may not be physically separated, and the components shown as modules may or may not be physical units, that is, they may be located in one place or distributed on multiple network units. Some or all of the units may be selected according to actual needs to achieve the purpose of the solution of this embodiment.

[0056] In addition, each functional module in each embodiment of the present invention may be integrated into one processing module, or each module may exist physically separately, or two or more modules may be integrated into one module. The above-mentioned integrated module may be implemented in the form of hardware or in the form of software functional modules.

[0057] The above are only implementation methods of the present application, and are not intended to limit the patent scope of the present application. Any equivalent structure or equivalent process transformation made using the contents of the present application specification and drawings, or directly or indirectly applied in other related technical fields, are also included in the patent protection scope of the present application.

Claims

1. A method for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis, characterized in that: The method is performed by a computer and comprises the following steps: Acquiring data: Acquiring the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins in samples of patients with radiation enteritis after treatment with CCDC71L inhibitors; Processing data: inputting the expression data obtained above into a constructed evaluation model, wherein the evaluation model predicts the therapeutic effect of CCDC71L inhibitor on patients with radiation enteritis based on the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins; Output the result.

2. The method according to claim 1, characterized in that The steps for constructing the evaluation model are as follows: Acquiring expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins; the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins are from untreated radiation enteritis patients and radiation enteritis patients treated with CCDC71L inhibitors; inputting the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins into a machine learning algorithm to construct an evaluation model; Preferably, the step of constructing the evaluation model also includes verifying the model effectiveness, and the method of verifying the model effectiveness includes a ROC curve.

3. The method according to claim 1 or 2, characterized in that: The ferroptosis-related proteins include one or more of the following: ACSL4, GPX4, FTH1; The lipid metabolism related proteins include one or more of the following: FADS2, SCD1.

4. The method according to claim 2, characterized in that: The machine learning algorithm includes an algorithm model developed using various development tools; Preferably, the development tools include but are not limited to TensorFlow, Scikit Learn, PyTorch, OpenNN, RapidMiner, Azure Machine Learning, Apache Mahout, Shogun, KNIME, Vertex AI, H2Oai, Anaconda, Keras, Tableau, Fast.ai, Catalyst, Amazon ML, MLJAR, Spell; Preferably, the algorithm model includes but is not limited to a linear regression model, a logistic regression model, a Lasso regression model, a Ridge regression model, a linear discriminant analysis model, a nearest neighbor model, a decision tree model, a perceptron model, a neural network model, a support vector machine model, a naive Bayes model, an AdaBoost model, a GBDT model, an XGBoost model, a LightGBM model, a CatBoost model, and a random forest model.

5. The method according to any one of claims 1 to 3, characterized in that: The evaluation model obtains results through the following criteria: When the expression level of any one or more of ACSL4, FADS2, and SCD1 is lower than a threshold value or the expression level of any one or more of GPX4 and FTH1 is higher than a threshold value, a classification result is obtained that the CCDC71L inhibitor is effective in treating radiation enteritis patients; When the expression levels of any one or more of ACSL4, FADS2, and SCD1 are higher than a threshold or the expression levels of any one or more of GPX4 and FTH1 are lower than a threshold, a classification result is obtained that CCDC71L inhibitor is ineffective in treating radiation enteritis patients.

6. A system for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis, characterized in that: The system comprises: Data acquisition unit: used to obtain the expression data of ferroptosis-related proteins and / or lipid metabolism-related proteins in samples of patients with radiation enteritis after treatment with CCDC71L inhibitors; Data classification unit: used for classifying and predicting the data obtained by the data acquisition unit through the evaluation model obtained by the construction method described in claim 2, and obtaining a classification result of whether the CCDC71L inhibitor is effective in treating radiation enteritis patients; Result output unit: used to output classification results.

7. The system according to claim 6, characterized in that The ferroptosis-related proteins include one or more of the following: ACSL4, GPX4, FTH1; The lipid metabolism related proteins include one or more of the following: FADS2, SCD1.

8. A computer device, characterized in that: The device comprises: A memory and a processor, wherein the memory is used to store program instructions; the processor is used to call the program instructions, and when the program instructions are executed, the method for evaluating the therapeutic effect of CCDC71L inhibitor on radiation enteritis described in any one of claims 1-5 is implemented.

9. A computer-readable storage medium, characterized in that: The computer-readable storage medium stores a computer program, and when the computer program is executed by a processor, the method for evaluating the therapeutic effect of a CCDC71L inhibitor on radiation enteritis according to any one of claims 1 to 5 is implemented.

10. Use of a CCDC71L inhibitor or a pharmaceutical composition containing a CCDC71L inhibitor in the preparation of the following products: 1) Products that inhibit ferroptosis; 2) Products that relieve lipid metabolism disorders; 3) Products that inhibit the expression of ACSL4, FADS2, and / or SCD1; 4) Products that promote GPX4 or FTH1 expression.

Images